VIA
JUNO

Vident Investment Advisory’s Juno Therapeutics, Inc. JUNO Stock Holding History

Vident Investment Advisory’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-25,207
Closed -$1.43M – 967
2017
Q4 		$1.43M Sell
25,207
-23,354
-48% -$1.16M 0.06% 318
2017
Q3 		$2.4M Sell
48,561
-916
-2% -$31.2K 0.13% 250
2017
Q2 		$1.48M Buy
49,477
+2,101
+4% +$51.8K 0.12% 276
2017
Q1 		$1.05M Buy
47,376
+7,896
+20% +$169K 0.1% 304
2016
Q4 		$744K Buy
39,480
+23,704
+150% +$580K 0.09% 305
2016
Q3 		$473K Hold
15,776
– – 0.06% 368
2016
Q2 		$606K Sell
15,776
-14,544
-48% -$604K 0.09% 356
2016
Q1 		$1.15K Buy
30,320
+14,071
+87% +$490K 0.07% 347
2015
Q4 		$714K Buy
+16,249
New +$806K 0.09% 345

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Vident Investment Advisory's JUNO Position: Q1 2018 in Review

Vident Investment Advisory sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 25,207 shares — an estimated $1.43M sold.

Vident Investment Advisory first reported a position in JUNO in Q4 2015 and held it in 9 quarters. The position peaked at $2.4M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Vident Investment Advisory reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Vident Investment Advisory sold 25,207 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $1.43M.
  • Vident Investment Advisory first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 9 quarters.
  • Vident Investment Advisory's Juno Therapeutics, Inc. position peaked at $2.4M in Q3 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Vident Investment Advisory's 13F filing for Q1 2018, filed 14 May 2018.